美罗培南每8小时给药500毫克后在血浆和斑蝥素诱导的皮肤水疱液中的药代动力学特征。
Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.
作者信息
Maglio Dana, Teng Renli, Thyrum Per T, Nightingale Charles H, Nicolau David P
机构信息
Center for Anti-Infective Research and Development, Division of Infectious Diseases, Office for Research, Hartford Hospital, Hartford, Connecticut 06102, USA.
出版信息
Antimicrob Agents Chemother. 2003 May;47(5):1771-3. doi: 10.1128/AAC.47.5.1771-1773.2003.
Abstract
The pharmacokinetic disposition of meropenem, administered at 500 mg every 8 h, in plasma and cantharidin-induced blister fluid is described. Peak meropenem concentrations in blister fluid lagged behind peak meropenem concentrations in plasma, while a lower elimination rate from blister fluid was also noted. The mean penetration of meropenem into blister fluid was 67%. The pharmacokinetic profile of meropenem in blister fluid supports the utility of this dose in the management of skin and soft tissue infections.
摘要
描述了每8小时给予500mg美罗培南后，其在血浆和斑蝥素诱导的水疱液中的药代动力学特征。水疱液中美罗培南的峰值浓度滞后于血浆中美罗培南的峰值浓度，同时还注意到水疱液中的消除率较低。美罗培南进入水疱液的平均渗透率为67%。美罗培南在水疱液中的药代动力学特征支持该剂量在治疗皮肤和软组织感染中的效用。
相似文献
1
Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.美罗培南每8小时给药500毫克后在血浆和斑蝥素诱导的皮肤水疱液中的药代动力学特征。
Antimicrob Agents Chemother. 2003 May;47(5):1771-3. doi: 10.1128/AAC.47.5.1771-1773.2003.
2
[Skin penetration of sulfamethoxazole and trimethoprim after oral administration].口服给药后磺胺甲恶唑和甲氧苄啶的皮肤渗透情况
Ann Acad Med Stetin. 2002;48:59-73.
3
Ketoconazole concentrations in human skin blister fluid and plasma.酮康唑在人皮肤水疱液和血浆中的浓度。
Int J Clin Pharmacol Ther Toxicol. 1984 Jul;22(7):371-4.
4
Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion.美罗培南在持续输注和间歇输注过程中血清及水疱抽吸液中的药代动力学
J Antimicrob Chemother. 1991 Dec;28(6):911-8. doi: 10.1093/jac/28.6.911.
5
Pharmacokinetics of dalbavancin in plasma and skin blister fluid.达巴万星在血浆和皮肤疱液中的药代动力学。
J Antimicrob Chemother. 2007 Sep;60(3):681-4. doi: 10.1093/jac/dkm263. Epub 2007 Jul 12.
6
Penetration of tinidazole into skin blister fluid following its oral administration.口服替硝唑后其在皮肤水疱液中的渗透情况。
Eur J Clin Pharmacol. 1992;43(5):523-6. doi: 10.1007/BF02285095.
7
Plasma pharmacokinetics and tissue fluid concentrations of meropenem after intravenous and subcutaneous administration in dogs.美罗培南在犬静脉注射和皮下注射后的血浆药代动力学及组织液浓度
Am J Vet Res. 2002 Dec;63(12):1622-8. doi: 10.2460/ajvr.2002.63.1622.
8
Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?在接受连续肾脏替代治疗的危重症患者中，美罗培南的间质液浓度与血浆浓度是否相当？
J Antimicrob Chemother. 2015 Feb;70(2):528-33. doi: 10.1093/jac/dku413. Epub 2014 Oct 21.
9
Plasma and skin blister fluid concentrations of metronidazole and its hydroxy metabolite after oral administration.口服给药后甲硝唑及其羟基代谢物的血浆和皮肤水疱液浓度。
Pol J Pharmacol. 1996 Jan-Feb;48(1):47-52.
10
[Pharmacokinetics of meropenem administered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration].[接受持续静脉-静脉血液滤过的患者中延长输注时间给药的美罗培南的药代动力学]
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2012 Mar;24(3):145-8.
引用本文的文献
1
Dosage Optimization Using Physiologically Based Pharmacokinetic Modeling for Pediatric Patients with Renal Impairment: A Case Study of Meropenem.使用基于生理的药代动力学模型对肾功能不全儿科患者进行剂量优化：美罗培南的案例研究
AAPS PharmSciTech. 2025 Jan 16;26(1):38. doi: 10.1208/s12249-024-03026-y.
2
Influence of Antibiotics on Functionality and Viability of Liver Cells In Vitro.抗生素对体外肝细胞功能和活力的影响。
Curr Issues Mol Biol. 2022 Oct 3;44(10):4639-4657. doi: 10.3390/cimb44100317.
3
Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.应用生理药代动力学模型预测儿科患者体内美罗培南、黏菌素和舒巴坦的组织暴露量。
Clin Pharmacokinet. 2022 Oct;61(10):1427-1441. doi: 10.1007/s40262-022-01161-y. Epub 2022 Aug 10.
4
Antibiotics in Necrotizing Soft Tissue Infections.坏死性软组织感染中的抗生素
Antibiotics (Basel). 2021 Sep 13;10(9):1104. doi: 10.3390/antibiotics10091104.
5
Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.哌拉西林和美罗培南治疗药物监测在常规临床实践中的应用：危重症患者的前瞻性队列研究。
Eur J Hosp Pharm. 2020 Mar;27(e1):e30-e35. doi: 10.1136/ejhpharm-2018-001713. Epub 2019 Feb 27.
6
Validation of the cantharidin-induced skin blister as an in vivo model of inflammation.验证斑蝥素诱导的皮肤水疱作为炎症的体内模型。
Br J Clin Pharmacol. 2011 Dec;72(6):912-20. doi: 10.1111/j.1365-2125.2011.04020.x.
7
Meropenem in the treatment of complicated skin and soft tissue infections.美罗培南治疗复杂性皮肤及软组织感染。
Ther Clin Risk Manag. 2006 Dec;2(4):401-15. doi: 10.2147/tcrm.2006.2.4.401.
8
Tissue penetration of telavancin after intravenous administration in healthy subjects.替考拉宁在健康受试者静脉给药后的组织穿透情况。
Antimicrob Agents Chemother. 2006 Feb;50(2):788-90. doi: 10.1128/AAC.50.2.788-790.2006.
9
Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations.多次静脉给药后健康受试者血清和皮肤水疱液中替加环素的药代动力学特征。
Antimicrob Agents Chemother. 2005 Apr;49(4):1629-32. doi: 10.1128/AAC.49.4.1629-1632.2005.
本文引用的文献
1
Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.美罗培南与亚胺培南/西司他丁作为重症监护病房严重细菌感染经验性单药治疗的比较
Clin Microbiol Infect. 2000 Jun;6(6):294-302. doi: 10.1046/j.1469-0691.2000.00082.x.
2
Meropenem: clinical response in relation to in vitro susceptibility.美罗培南：与体外药敏性相关的临床反应
Clin Microbiol Infect. 2000 Apr;6(4):185-94. doi: 10.1046/j.1469-0691.2000.00062.x.
3
Meropenem: a review of its use in patients in intensive care.美罗培南：对其在重症监护患者中应用的综述
Drugs. 2000 Mar;59(3):653-80. doi: 10.2165/00003495-200059030-00016.
4
The pharmacodynamics of beta-lactams.β-内酰胺类药物的药效学
Clin Infect Dis. 1998 Jul;27(1):10-22. doi: 10.1086/514622.
5
Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.美罗培南与亚胺培南/西司他丁作为经验性单药治疗严重医院感染的前瞻性、随机、多中心研究。
Eur J Clin Microbiol Infect Dis. 1997 Nov;16(11):789-96. doi: 10.1007/BF01700407.
6
Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group.美罗培南或头孢他啶联合妥布霉素经验性治疗医院获得性下呼吸道感染：一项随机研究。美罗培南下呼吸道感染组。
Crit Care Med. 1997 Oct;25(10):1663-70. doi: 10.1097/00003246-199710000-00015.
7
Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.美罗培南与亚胺培南/西司他丁治疗住院皮肤及软组织感染患者的疗效比较
South Med J. 1995 Apr;88(4):397-404. doi: 10.1097/00007611-199504000-00003.
8
Simultaneous comparison of three methods for assessing ceftazidime penetration into extravascular fluid.三种评估头孢他啶向血管外液渗透方法的同步比较。
Antimicrob Agents Chemother. 1982 Dec;22(6):995-8. doi: 10.1128/AAC.22.6.995.
9
Extravascular penetration of highly protein-bound flucloxacillin.高蛋白结合率氟氯西林的血管外渗透
Antimicrob Agents Chemother. 1986 Nov;30(5):729-32. doi: 10.1128/AAC.30.5.729.
10
Effect of protein binding on drug penetration into blister fluid.蛋白结合对药物渗透至水疱液中的影响。
Antimicrob Agents Chemother. 1988 Jan;32(1):128-30. doi: 10.1128/AAC.32.1.128.
Zotero 插件